Baudax Bio regains compliance with Nasdaq's listing rules

• Baudax Bio (NASDAQ:BXRX) has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2).
• Nasdaq staff made this determination of compliance after the company's bid price closed above $1.00/share for ten consecutive business days from Feb. 16, 2022 to Mar. 2, 2022.
• BXRX -1.16% pre-market
• Last week, Baudax Bio won a new U.S. patent for pain therapy